Tuesday December 22, 2020
22 Dec 2020 – Update on the recently acquired NTCD-M3 programme
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Update on the recently acquired NTCD-M3 biotherapeutic clinical programme for prevention of recurrence of C. difficile infections Brighton, United Kingdom – 22 […]
Monday December 21, 2020